Alzheon steps back from an IPO, further than ever from a PhIII Alzheimer’s study
Alzheon won’t be profiting from an IPO soon.
The tiny biotech, which has been trying to fund a late-stage trial for a once-failed drug called …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
